Mylan gets FDA OK to market generic version of Norvasc

Share this article:
Generic drug maker Mylan received final FDA approval for a generic version of Pfizer's blockbuster blood-pressure medicine Norvasc.
Mylan said in a statement that since it was the first generic company to file with the FDA on all strengths of Norvasc, the company is eligible for 180 days of market exclusivity.
The approval covers tablets of Norvasc's active ingredient, amlodipine besylate, in strengths of 2.5 milligrams, 5 milligrams, and 10 milligrams.
Mylan said the exclusivity period will begin with its launch of the product or with the resolution of a patent lawsuit between it and Pfizer, whichever comes first.
Two patents protect Norvasc -- the first protects the amlodipine molecule, and the second protects the besylate salt formulation of the molecule.
The patents expire Jan. 31, 2007, and Sept. 25, 2007, respectively.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions